Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory studyHaoran Xia, Gening Jiang, Yuming Zhu et al.|Signal Transduction and Targeted Therapy|2024Cited by 30
Utility of 18F-FDG PET/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancerFenghui Zhuang, Deping Zhao, E Haoran et al.|Lung Cancer|2023Cited by 25